Enterprise Value
-110.2M
Cash
158.5M
Avg Qtr Burn
-14.19M
Short % of Float
0.00%
Insider Ownership
5.96%
Institutional Own.
61.38%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ATL001 (TIL cNeT (Neoantigen Reactive T cells)) Details Non-small cell lung carcinoma, Cancer, Solid tumor/s | Phase 1/2 Data readout | |
ATL001 (Neoantigen Reactive T cells) Details Melanoma, Cancer, Solid tumor/s | Phase 1/2 Data readout |